Biogen

Biogen, founded in 1978, is a prominent U.S.-based biotechnology firm specializing in the discovery, development, and commercialization of therapies for serious neurological and neurodegenerative diseases. The company maintains a robust portfolio targeting conditions such as multiple sclerosis, spinal muscular atrophy, and various rare neurological disorders. By leveraging advanced research in neuroscience, biologics, and gene-based therapies, Biogen continues to drive innovation within the global pharmaceutical and healthcare sectors.

Operating on a global scale, Biogen manages 59 locations to support its extensive research and commercialization efforts. The company employs a workforce of 5,000-10,000 employees dedicated to advancing human health through scientific breakthroughs. Learn about Biogen's global headquarters for detailed information regarding their operational footprint in Cambridge, Massachusetts. This strategic presence enables the firm to maintain its competitive edge in a complex, highly regulated market environment.

Biogen competes with major industry players such as Regeneron, Gilead Sciences, and Amgen, consistently focusing on high-impact medical solutions. The organization prioritizes inclusion and professional development, fostering a collaborative environment for its diverse scientific and operational teams. Meet Biogen's team to gain insights into the leadership and organizational structure driving the company's mission. With a commitment to patient advocacy and innovative drug development, Biogen remains a key entity in the evolving landscape of modern biotechnology and therapeutic science.